Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)
| Market Cap | 1.75B+23.3% |
| Revenue (ttm) | 335.41M+36.3% |
| Net Income | -17.16M+46.4% |
| EPS | -0.10+52.6% |
| Shares Out | 172.64M |
| PE Ratio | n/a |
| Forward PE | 29.47 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 434,078.901 |
| Open | 10.10 |
| Previous Close | 10.11 |
| Day's Range | 10.01 - 10.25 |
| 52-Week Range | 5.25 - 11.33 |
| Beta | 0.84 |
| Analysts | Buy |
| Price Target | 15.00(+47.86%) |
| Earnings Date | Nov 5, 2026 |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About XERS
Xeris Biopharma Holdings, Inc. operates as a biopharmaceutical company, focusing on the development and commercialization of therapeutic solutions for individuals across the fields of endocrinology, neurology, and gastroenterology. Its current portfolio includes: Gvoke: A ready-to-administer liquid glucagon designed to treat severe hypoglycemia. Keveyis: A therapy addressing hyperkalemic, hypokalemic, and related forms of primary periodic paralysis. Recorlev: A cortisol synthesis inhibitor approved for managing endogenous hypercortisolemia in adult patients with Cushing's syndrome. Beyond its marketed products, the company maintains an active development pipeline. This pipeline seeks to broaden the applications and indications for existing treatments and introduce novel pharmaceuticals leveraging its proprietary XeriSol and XeriJect formulation technology platforms. Founded in 2005, Xeris Biopharma is headquartered in Chicago, Illinois.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$XERS stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in XERS holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by XERS's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
XERS Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New XERS patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to XERS from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in XERS
| ETF | Est. Holding Size |
|---|---|
| IWMiShares Russell 2000 ETF | $44.85M |
| VTIVanguard Morningstar Total Stock Market ETF | $43.83M |
| VXFVanguard Extended Market ETF | $16.95M |
| IWOiShares Russell 2000 Growth ETF | $16.09M |
| XPHState Street SPDR S&P Pharmaceuticals ETF | $13.09M |
| FYCFirst Trust Small Cap Growth AlphaDEX Fund | $12.80M |
Estimated from each fund’s disclosed top holdings × AUM
XERS Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from XERS’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score